Oral vaccine strategy used modified bacterium to combat colorectal cancer

Oral vaccine strategy used modified bacterium to combat colorectal cancer

A research team investigating the use of the bacterium Listeria monocytogenes against colorectal cancer has discovered a way to build a modified version of Listeria as an oral vaccine to prime the immune system directly within the gut, where anti-tumor cells are then generated. Details of the work, led by Stony Brook immunologist Brian Sheridan, Ph.D., are published in the Journal for the ImmunoTherapy of Cancer.

Oral Listeria Vaccine Boosts ICI Therapy Response in Colorectal Cancer

Researchers at Stony Brook University have created an oral vaccine from a modified strain of Listeria monocytogenes (Lm) that can prime tumor-specific immune responses in the gut and improve control of colorectal cancer (CRC) in preclinical models. The research, published in the Journal for ImmunoTherapy of Cancer, demonstrated that the orally delivered vaccine directly targeted the gut and intestinal tissue and generated a robust anti-tumor CD …